Cagrilintide
Long-acting amylin analog studied in metabolic and appetite regulation research, often investigated alongside GLP-1 agonists.
Research Areas
Scientific Background
Cagrilintide is a long-acting amylin analog that acts on amylin and calcitonin receptors to promote satiety and slow gastric emptying. It has been studied extensively in clinical trials, particularly in combination with semaglutide (CagriSema), for metabolic and weight-management research.
Purity & Provenance
Why quality matters for research validity
Cagrilintide is a long-acting acylated amylin analog. Verify HPLC ≥98% purity and sequence confirmation.
Areas of Investigation
Laboratory Information
Technical specifications for research settings
This compound is intended for qualified scientific research only. Not for human or veterinary use. Not for diagnostic or therapeutic applications. Researchers must comply with all applicable regulations in their jurisdiction.
Store lyophilized at -20°C. Protect from light.
Lyophilized powder
>98% by HPLC
Soluble in bacteriostatic water
For in vitro metabolic research applications.
Deepen Your Research
Published literature and clinical trial registries
Published Literature
Lau et al. (2021, The Lancet) reported that cagrilintide dose-dependently reduced body weight in phase 2 clinical trials. CagriSema (cagrilintide + semaglutide) has advanced through phase 3 metabolic research programs.
Regulatory Classification
Cagrilintide is an investigational compound in clinical trials, not FDA-approved. Available for qualified research purposes only.
Important Research Notice
This information is compiled from scientific literature for educational purposes only. This website does not sell, distribute, or recommend any compounds for human use. All compounds discussed are for qualified research purposes only.